Pipeline

main office: Madison, wi

arrow

general manager:
Meet Jake Orville

mayo clinic logo
arrow

mayo clinic COLLABORATION

strengths icon

Key Strengths

Ability to evaluate multiple classes of biomarkers

Proprietary DNA chemistry

State-of-the-art labs

Flexible, automated platform

The Pipeline business is responsible for advancing our future diagnostic tests from early research to product development and availability. Its progress is fueled by our long-standing collaboration with Mayo Clinic, our experienced R&D team, and our automated, accurate, and differentiated platform.

cancer test icon

Liver Cancer Test

One of the liquid biopsy tests we’re developing in collaboration with Mayo Clinic is for liver cancer, a disease that kills 30,000 Americans and 780,000 people world-wide each year. There are more than 3 million people in the U.S. at high risk of the disease who should be tested regularly. Our goal is to improve upon the accuracy and convenience of the existing guideline-recommended test options. Patients fail to comply with recommended testing more than two-thirds of the time. A more accurate and convenient test may encourage more people to get tested, improve outcomes, and unlock a large market opportunity. We plan to make the test available in 2021 and generate real-world evidence to support clinical guideline inclusion, broad insurance coverage, and adoption over time.

Source: American Cancer Society and World Health Organization

Plan to ADDRESS 4 of the top 6 cancer
killers
in the US

cancer killers graph

Note: expect to make liver cancer test available in 2021

Source: American Cancer Society, Cancer Facts & Figures 2020; all figures annual

Researching biomarkers across 15 deadly cancers in collaboration with Mayo Clinic, with promising early results in liver, pancreatic, esophageal, and bladder.

liver iconpancreatic iconesophageal iconbladder iconovarian iconcervical icon
colorectal iconprostate iconbreast icon
stomach iconlung iconlymphoma iconmelanoma iconkidney iconuterine icon

Forward-Looking Statements

This report contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are intended to be covered by the"safe harbor" created by those sections. Forward-looking statements, which are based on certain assumptions and describe our future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as "believe," "expect,""may," "will," "should," "would," "could," "seek," "intend," "plan," "goal," "project," "estimate," "anticipate" or other comparable terms. All statements other than statements of historical facts included in this report regarding our strategies, prospects, expectations, goals, financial condition, operations, costs, plans and objectives are forward-looking statements. Examples of forward-looking statements include, among others, statements we make regarding expected growth opportunities and market share, future operating results, anticipated results of our sales, marketing and patient adherence efforts, expectations concerning payer reimbursement, and the anticipated results of our product development efforts. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Actual results, conditions and events may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause actual results, conditions and events to differ materially from those indicated in the forward-looking statements include, among others, the risks and uncertainties described in the Risk Factors and in Management's Discussion and Analysis of Financial Condition and Results of Operations sections of our most recently filed Annual Report on Form 10-K and our subsequently filed Quarterly Reports on Form 10-Q. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.